Core Insights - Samsung Bioepis and Epis NexLab have signed a research collaboration and license agreement with G2GBIO to develop novel assets, including long-acting semaglutide, utilizing G2GBIO's proprietary microsphere technology [1][1][1] Group 1: Agreement Details - Samsung Bioepis will receive exclusive licensing rights for the long-acting semaglutide asset and an option to license another asset from G2GBIO [1][1] - The agreement includes first negotiation rights for three additional novel assets to be determined [1][1] - Epis NexLab will co-develop the long-acting microsphere drug delivery platform using G2GBIO's technology [1][1] Group 2: Company Background - Samsung Bioepis, established in 2012, is a biopharmaceutical company focused on making healthcare accessible through innovative product development [1][1] - The company aims to become a leading biopharmaceutical entity with a broad pipeline covering various therapeutic areas, including immunology, oncology, and endocrinology [1][1]

Core Viewpoint - Samsung Bioepis has commenced the direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe [1] Company Summary - Samsung Bioepis is actively entering the European market with its biosimilar product BYOOVIZ® [1]

Group 1 - Samsung Bioepis' Byooviz PFS has received European approval, marking a significant milestone for the company in the biopharmaceutical sector [1] - This approval is expected to enhance Samsung Bioepis' position in the biosimilar market, particularly in Europe [1] - The company aims to leverage this approval to expand its product offerings and increase market share in the competitive landscape of biologics [1]